MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ
1.040
-0.050
-4.59%
After Hours: 1.074 +0.034 +3.25% 19:49 11/06 EST
OPEN
1.090
PREV CLOSE
1.090
HIGH
1.130
LOW
0.9800
VOLUME
12.63M
TURNOVER
--
52 WEEK HIGH
4.460
52 WEEK LOW
0.9800
MARKET CAP
359.31M
P/E (TTM)
-1.6661
1D
5D
1M
3M
1Y
5Y
1D
Allogene (ALLO) Q3 2026 Earnings Call Transcript
The Motley Fool · 1d ago
RBC Capital Sticks to Their Buy Rating for Allogene Therapeutics (ALLO)
TipRanks · 1d ago
Allogene Therapeutics Q3 2026 Earnings Call Transcript
Benzinga · 1d ago
Allogene Therapeutics Q3 EPS $(0.15), Inline
Benzinga · 1d ago
Here are the major earnings after the close Thursday
Seeking Alpha · 2d ago
Allogene's Autoimmune Data May Already Be Priced Into Expectations
Barchart · 2d ago
Weekly Report: what happened at ALLO last week (1026-1030)?
Weekly Report · 5d ago
Weekly Report: what happened at ALLO last week (1019-1023)?
Weekly Report · 10/26 09:41
More
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Webull offers Allogene Therapeutics Inc stock information, including NASDAQ: ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.